Glycated hemoglobin (hemoglobin A1c, HbA1c, A1C, or Hb1c; sometimes also HbA1c or HGBA1C) is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods. It is formed in a non-enzymatic glycation pathway by hemoglobin's exposure to plasma glucose. HbA1c is a measure of the beta-N-1-deoxy fructosyl component of hemoglobin.[1][2] Normal levels of glucose produce a normal amount of glycated hemoglobin. As the average amount of plasma glucose increases, the fraction of glycated hemoglobin increases in a predictable way. This serves as a marker for average blood glucose levels over the previous 3 months prior to the measurement as this is the lifespan of red blood cells.
In diabetes mellitus, higher amounts of glycated hemoglobin, indicating poorer control of blood glucose levels, have been associated with cardiovascular disease, nephropathy, and retinopathy. Monitoring HbA1c in type 1 diabetic patients may improve outcomes.[3]
Contents
- 1 History
- 2 Principle
- 3 Measuring HbA1c
- 4 Interpretation of results
- 5 Indications and use
- 6 Modification by exercise training
- 7 Standardization and traceability
- 8 See also
- 9 References
- 10 External links
History
Hemoglobin A1c was first separated from other forms of hemoglobin by Huisman and Meyering in 1958 using a chromatographic column.[4] It was first characterized as a glycoprotein by Bookchin and Gallop in 1968.[5] Its increase in diabetes was first described in 1969 by Samuel Rahbar et al.[6] The reactions leading to its formation were characterized by Bunn and his coworkers in 1975.[7]
The use of hemoglobin A1c for monitoring the degree of control of glucose metabolism in diabetic patients was proposed in 1976 by Anthony Cerami, Ronald Koenig and coworkers.[8]
Principle
Glycation of proteins is a frequent occurrence, but in the case of hemoglobin, a nonenzymatic reaction occurs between glucose and the N-end of the beta chain. This forms a Schiff base which is itself converted to 1-deoxyfructose. This rearrangement is an example of an Amadori rearrangement.
When blood glucose levels are high, glucose molecules attach to the hemoglobin in red blood cells. The longer hyperglycemia occurs in blood, the more glucose binds to hemoglobin in the red blood cells and the higher the glycated hemoglobin.
Once a hemoglobin molecule is glycated, it remains that way. A buildup of glycated hemoglobin within the red cell, therefore, reflects the average level of glucose to which the cell has been exposed during its life-cycle. Measuring glycated hemoglobin assesses the effectiveness of therapy by monitoring long-term serum glucose regulation.
A1c is a weighted average of blood glucose levels during the life of the red blood cells (120 days). Therefore glucose levels on days nearer to the test contribute substantially more to the level of A1c than the levels in days further from the test.[9]
This is also supported by data from practice showing that HbA1c levels improved significantly by 20 days from the start of the intensification of glucose-lowering treatment.[10]
Measuring HbA1c
A number of techniques are used to measure hemoglobin A1c.
Laboratories use:
- High-performance liquid chromatography (HPLC): The HbA1c result is calculated as a ratio to total hemoglobin by using a chromatogram.
- Immunoassay
- Enzymatic
- Capillary electrophoresis
- Boronate affinity chromatography
Point of care (e.g., doctor's office) devices use:
- Immunoassay
- Boronate affinity chromatography
In the United States, HbA1c testing laboratories are certified by the National Glycohemoglobin Standardization Program (NGSP) to standardise them against the results of the 1993 Diabetes Control and Complications Trial (DCCT).[11] An additional percentage scale, Mono S is in use by Sweden and KO500 is in Japan.[12][13]
Switch to IFCC units
The American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD) and International Diabetes Federation (IDF) have agreed that, in the future, HbA1c is to be reported in the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) units.[14] IFCC reporting was introduced in Europe except for the UK in 2003;[15] the UK carried out dual reporting from 1 June 2009 [16] until 1 October 2011.
Conversion between DCCT and IFCC is by the following equation:[17]
| IFCC-HbA1c |
DCCT-HbA1c |
Mono S- HbA1c[13] |
| (mmol/mol) |
(%) |
(%) |
| 10 |
3.1 |
2.0 |
| 20 |
4.0 |
2.9 |
| 30 |
4.9 |
3.9 |
| 40 |
5.8 |
4.8 |
| 45 |
6.3 |
5.3 |
| 50 |
6.7 |
5.8 |
| 55 |
7.2 |
6.3 |
| 60 |
7.6 |
6.8 |
| 65 |
8.1 |
7.2 |
| 70 |
8.6 |
7.7 |
| 80 |
9.5 |
8.7 |
| 90 |
10.4 |
9.6 |
| 100 |
11.3 |
10.6 |
Interpretation of results
Laboratory results may differ depending on the analytical technique, the age of the subject, and biological variation among individuals. Two individuals with the same average blood sugar can have HbA1c values that differ by as much as 3 percentage points.[citation needed]
Results can be unreliable in many circumstances, such as after blood loss, for example, after surgery, blood transfusions, anemia, or high erythrocyte turnover; in the presence of chronic renal or liver disease; after administration of high-dose vitamin C; or erythropoetin treatment.[18] In general, the reference range (that found in healthy persons), is about 20–40 mmol/mol (4–5.9 DCCT %).[19]
Higher levels of HbA1c are found in people with persistently elevated blood sugar, as in diabetes mellitus. While diabetic patient treatment goals vary, many include a target range of HbA1c values. A diabetic person with good glucose control has a HbA1c level that is close to or within the reference range.
The International Diabetes Federation and the American College of Endocrinology recommend HbA1c values below 48 mmol/mol (6.5 DCCT %), while the American Diabetes Association recommends HbA1c be below 53 mmol/mol (7.0 DCCT %) for most patients.[20] Recent results from large trials suggest that a target below 53 mmol/mol (7 DCCT %) for older adults with type 2 diabetes may be excessive: Below 53 mmol/mol (7 DCCT %) the health benefits of reduced A1C become smaller, and the intensive glycemic control required to reach this level leads to an increased rate of dangerous hypoglycemic episodes.[21]
A retrospective study of 47,970 old type 2 diabetes patients found that patients with an HbA1c more than 48 mmol/mol (6.5 DCCT %) had an increased mortality rate,[22] but a later international study contradicted these findings.[23][24][25]
A review of the UKPDS, ACCORD (Action to Control Cardiovascular Risk in Diabetes), ADVANCE and VADT (Veterans Affairs Diabetes Trials) estimated that the risks of the main complications of diabetes (diabetic retinopathy, diabetic nephropathy, diabetic neuropathy and macrovascular disease) decreased by approximately 3% for every 1 mmol/mol decrease in HbA1c.[26]
Practitioners must consider an individual patient's health, their risk of hypoglycemia, and their specific health risks when setting a target HbA1c level. Because patients are responsible for averting or responding to their own hypoglycemic episodes, the patient's input and the doctor's assessment of the patient's self-care skills are also important.
Persistent elevations in blood sugar (and, therefore, HbA1c) increase the risk of long-term vascular complications of diabetes such as coronary disease, heart attack, stroke, heart failure, kidney failure, blindness, erectile dysfunction, neuropathy (loss of sensation, especially in the feet), gangrene, and gastroparesis (slowed emptying of the stomach). Poor blood glucose control also increases the risk of short-term complications of surgery such as poor wound healing.
Lower-than-expected levels of HbA1c can be seen in people with shortened red blood cell lifespan, such as with glucose-6-phosphate dehydrogenase deficiency, sickle-cell disease, or any other condition causing premature red blood cell death. Blood donation will result in rapid replacement of lost RBCs with newly formed red blood cells. Since these new RBCs will have only existed for a short period of time, their presence will lead HbA1c to underestimate the actual average levels. There may also be distortions resulting from blood donation which occurred as long as two months before due to an abnormal synchronization of the age of the RBCs, resulting in an older than normal average blood cell life (resulting in an overestimate of actual average blood glucose levels). Conversely, higher-than-expected levels can be seen in people with a longer red blood cell lifespan, such as with Vitamin B12 or folate deficiency.[27]
The approximate mapping between HbA1c values given in DCCT percentage (%) and eAG (estimated average glucose) measurements is given by the following equation:[18]
- eAG(mg/dl) = 28.7 × A1C − 46.7
eAG(mmol/l) = 1.59 × A1C − 2.59
Data in parentheses are 95% confidence intervals
| HbA1c |
eAG (estimated average glucose) |
| (%) |
(mmol/mol)[28] |
(mmol/L) |
(mg/dL) |
| 5 |
31 |
5.4 (4.2–6.7) |
97 (76–120) |
| 6 |
42 |
7.0 (5.5–8.5) |
126 (100–152) |
| 7 |
53 |
8.6 (6.8–10.3) |
154 (123–185) |
| 8 |
64 |
10.2 (8.1–12.1) |
183 (147–217) |
| 9 |
75 |
11.8 (9.4–13.9) |
212 (170–249) |
| 10 |
86 |
13.4 (10.7–15.7) |
240 (193–282) |
| 11 |
97 |
14.9 (12.0–17.5) |
269 (217–314) |
| 12 |
108 |
16.5 (13.3–19.3) |
298 (240–347) |
| 13 |
119 |
18.1 (15–21) |
326 (260–380) |
| 14 |
130 |
19.7 (16–23) |
355 (290–410) |
| 15 |
140 |
21.3 (17–25) |
384 (310–440) |
| 16 |
151 |
22.9 (19–26) |
413 (330–480) |
| 17 |
162 |
24.5 (20–28) |
441 (460–510) |
| 18 |
173 |
26.1 (21–30) |
470 (380–540) |
| 19 |
184 |
27.7 (23–32) |
499 (410–570) |
The 2010 American Diabetes Association Standards of Medical Care in Diabetes added the HbA1c ≥ 48 mmol/mol (≥6.5 DCCT %) as another criterion for the diagnosis of diabetes.[29]
Indications and use
Glycated hemoglobin testing is recommended for both (a) checking the blood sugar control in people who might be pre-diabetic and (b) monitoring blood sugar control in patients with more elevated levels, termed diabetes mellitus. There is a significant proportion of people who are unaware of their elevated HbA1c level before they have blood lab work.[30] For a single blood sample, it provides far more revealing information on glycemic behavior than a fasting blood sugar value. However, fasting blood sugar tests are crucial in making treatment decisions. The American Diabetes Association guidelines are similar to others in advising that the glycated hemoglobin test be performed at least two times a year in patients with diabetes that are meeting treatment goals (and that have stable glycemic control) and quarterly in patients with diabetes whose therapy has changed or that are not meeting glycemic goals.[31]
Glycated hemoglobin measurement is not appropriate where there has been a change in diet or treatment within 6 weeks. Likewise, the test assumes a normal red blood cell aging process and mix of hemoglobin subtypes (predominantly HbA in normal adults). Hence, people with recent blood loss, hemolytic anemia, or genetic differences in the hemoglobin molecule (hemoglobinopathy) such as sickle-cell disease and other conditions, as well as those that have donated blood recently, are not suitable for this test.
Due to glycated hemoglobin's variability (as shown in the table above), additional measures should be checked in patients at or near recommended goals. People with HbA1c values at 64 mmol/mol or less should be provided additional testing to determine whether the HbA1c values are due to averaging out high blood glucose (hyperglycemia) with low blood glucose (hypoglycemia) or the HbA1c is more reflective of an elevated blood glucose that does not vary much throughout the day. Devices such as continuous blood glucose monitoring allow people with diabetes to determine their blood glucose levels on a continuous basis, testing every few minutes. Continuous use of blood glucose monitors is becoming more common, and the devices are covered by many health insurance plans but not by Medicare in the United States. The supplies tend to be expensive, since the sensors must be changed at least weekly. Another test that is useful in determining if HbA1c values are due to wide variations of blood glucose throughout the day is 1,5 Anhydroglucitol, also known as GlycoMark. GlycoMark reflects only the times that the person experiences hyperglycemia above 180 mg/dL over a two-week period.
Concentrations of hemoglobin A1 (HbA1) are increased, both in diabetic patients and in patients with renal failure, when measured by ion-exchange chromatography. The thiobarbituric acid method (a chemical method specific for the detection of glycation) shows that patients with renal failure have values for glycated hemoglobin similar to those observed in normal subjects, suggesting that the high values in these patients are a result of binding of something other than glucose to hemoglobin.[32]
In autoimmune hemolytic anemia, concentrations of hemoglobin A1 (HbA1) is undetectable. Administration of prednisolone (PSL) will allow the HbA1 to be detected.[33] The alternative fructosamine test may be used in these circumstances and it also reflects an average of blood glucose levels over the preceding 2 to 3 weeks.
All the major institutions like International Expert Committee Report, drawn from the International Diabetes Federation (IDF), the European Association for the Study of diabetes (EASD), and the American Diabetes Association (ADA), suggests the HbA1c level of 48 mmol/mol (6.5 DCCT %) as a diagnostic level.[34] The Committee Report further states that, when HbA1c testing cannot be done, the fasting and glucose tolerance tests be done.
Diagnosis of diabetes during pregnancy continues to require fasting and glucose tolerance measurements for gestational diabetes, and not the glycated hemoglobin.
Modification by exercise training
A meta-analysis of research done to identify the effect of two different kinds of training programs (combined aerobic and eccentric resistance exercise program and aerobic exercise only) on the glycated hemoglobin levels of individuals with T2DM found that the effect of combining resistance exercise with aerobic exercise improved the glucose control more than just the aerobics alone, but it should be noted that BMI of the resistance plus aerobic exercise group decreased more than the aerobic only group.
The average effect of the training programs included reductions of glycated hemoglobin of 9 mmol/mol (0.8 percentage points), which was a result similar to that of long-term diet and drug or insulin therapy (which result in a reduction of 6.5–9.0 mmol/mol (i.e. 0.6–0.8 points).[35]
Standardization and traceability
Hemoglobin A1c is now standardized & traceable to IFCC methods HPLC-CE & HPLC-MS.
A new unit (mmol/mol) is used as part of this standardization. The standardized test does not however test for Iodine levels in the blood. Hypothyroidism or Iodine supplementation are known sources that artificially raise the A1c number. [1]
See also
- Advanced glycation end product
- Hemoglobin A2
References
- ^ Miedema K (2005). "Standardization of HbA1c and Optimal Range of Monitoring". SCANDINAVIAN JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION 240: 61–72. PMID 16112961.
- ^ Peterson KP, Pavlovich JG, Goldstein D, Little R, England J, Peterson CM (1998). "What is hemoglobin A1c? An analysis of glycated hemoglobins by electrospray ionization mass spectrometry". Clinical Chemistry (journal) 44 (9): 1951–1958. PMID 9732983.
- ^ Larsen ML, Hørder M, Mogensen EF (1990). "Effect of long-term monitoring of glycosylated haemoglobin levels in insulin-dependent diabetes mellitus". N. Engl. J. Med. 323 (15): 1021–5. doi:10.1056/NEJM199010113231503. PMID 2215560.
- ^ Huisman TH, Martis EA, Dozy A (1958). "Chromatography of hemoglobin types on carboxymethylcellulose". J. Lab. Clin. Med. 52 (2): 312–27. PMID 13564011.
- ^ Bookchin RM, Gallop PM (1968). "Structure of haemoglobin A1c: nature of the N-terminal beta chain blocking group". Biochem. Biophys. Res. Commun. 32 (1): 86–93. doi:10.1016/0006-291X(68)90430-0. PMID 4874776.
- ^ Rahbar S, Blumenfeld O, Ranney HM (1969). "Studies of an unusual hemoglobin in patients with diabetes mellitus". Biochem. Biophys. Res. Commun. 36 (5): 838–43. doi:10.1016/0006-291X(69)90685-8. PMID 5808299.
- ^ Bunn HF, Haney DN, Gabbay KH, Gallop PM (1975). "Further identification of the nature and linkage of the carbohydrate in haemoglobin A1c". Biochem. Biophys. Res. Commun. 67 (1): 103–9. doi:10.1016/0006-291X(75)90289-2. PMID 1201013.
- ^ Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A (1976). "Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus". N. Engl. J. Med. 295 (8): 417–20. doi:10.1056/NEJM197608192950804. PMID 934240.
- ^ "NGSP: HbA1c and eAG". www.ngsp.org. Retrieved 2015-10-28.
- ^ Sidorenkov G, Haaijer-Ruskamp FM, de Zeeuw D, Denig P (2011). "A longitudinal study examining adherence to guidelines in diabetes care according to different definitions of adequacy and timeliness.". PLoS ONE 6 (9): e24278. doi:10.1371/journal.pone.0024278. PMC 3169586. PMID 21931669.
- ^ Developing Point of care HbA1c tests for Diabetes monitoring, Barry Plant, Originally Published IVDT July/August 2008
- ^ [Clinical Chemistry 50:1 166–174 (2004)]
- ^ a b HbA1c in a new way By the Swedish Diabetes Association. Retrieved Mars 2011
- ^ Geistanger A, Arends S, Berding C, Hoshino T, Jeppsson JO, Little R, Siebelder C, Weykamp C (August 2008). "Statistical methods for monitoring the relationship between the IFCC reference measurement procedure for hemoglobin A1c and the designated comparison methods in the United States, Japan, and Sweden". Clin. Chem. 54 (8): 1379–85. doi:10.1373/clinchem.2008.103556. PMID 18539643.
- ^ Manley S, John WG, Marshall S (July 2004). "Introduction of IFCC reference method for calibration of HbA: implications for clinical care". Diabet. Med. 21 (7): 673–6. doi:10.1111/j.1464-5491.2004.01311.x. PMID 15209757.
- ^ "Standardisation of the reference method for the measurement of HbA1c to improve diabetes care" (PDF). The Association for Clinical Biochemistry and Diabetss UK. April 2008. Retrieved 2009-07-02.
- ^ "HbA1c Standardisation For Laboratory Professionals" (PDF). Diabetes UK. Retrieved 2009-07-02.
- ^ a b Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ (2008). "Translating the A1C assay into estimated average glucose values.". Diabetes Care 31 (8): 1473–8. doi:10.2337/dc08-0545. PMC 2742903. PMID 18540046.
- ^ "Hemoglobin A1c Test". MedicineNet.com. Retrieved 2007-12-26.
- ^ "Executive Summary: Standards of medical care in diabetes—2009". Diabetes Care 32: S6–S12. 2009. doi:10.2337/dc09-S006.
- ^ Lehman R, Krumholz HM (2009). "Tight control of blood glucose in long standing type 2 diabetes". Brit Med J 338: b800. doi:10.1136/bmj.b800.
- ^ doi:10.1016/S0140-6736(09)61969-3
- ^ "ADVANCE Study Contradicts ACCORD Findings". Diabetes Self-Management. 2008-03-07. Retrieved 2013-06-10.
- ^ "The largest ever study of diabetes shows intensive glucose control reduces serious complications – ADVANCE". Advance-trial.com. Retrieved 2013-06-10.
- ^ Heller, Simon R. (2009-11-01). "A Summary of the ADVANCE Trial". Diabetes Care 32 (Suppl 2): S357–S361. doi:10.2337/dc09-S339. ISSN 0149-5992. PMC 2811451. PMID 19875581.
- ^ Shubrook JH, Shubrook J (2010). "Risks and benefits of attaining HbA(1c) goals: Examining the evidence". The Journal of the American Osteopathic Association 110 (7 Suppl 7): eS7–e12. PMID 20644204.
- ^ Kilpatrick ES, Bloomgarden ZT, Zimmet PZ (2009). "Is haemoglobin A1c a step forward for diagnosing diabetes?". BMJ 339: b4432. doi:10.1136/bmj.b4432. PMID 19903702.
- ^ Change to HbA1c values at Diabetes UK, 2013
- ^ "Executive summary: Standards of medical care in diabetes—2010". Diabetes Care 33 (Suppl 1): S4–10. January 2010. doi:10.2337/dc10-S004. PMC 2797389. PMID 20042774.
- ^ Walid MS, Newman BF, Yelverton JC, Nutter JP, Ajjan M, Robinson JS (2009). "Prevalence of previously unknown elevation of glycated hemoglobin (HbA1c) in spine surgery patients and impact on length of stay and total cost". J Hosp Med 5 (1): NA. doi:10.1002/jhm.541. PMID 19753643.
- ^ American Diabetes Association (2007). "Standards of medical care in diabetes--2007". Diabetes Care 30 (Suppl 1): S4–S41. doi:10.2337/dc07-S004. PMID 17192377.
- ^ "Glycated Hemoglobin in Uremic Patients as Measured by Affinity and Ion-Exchange Chromatography" (PDF). clinchem.com. Retrieved 2009-08-31.
- ^ "Undetectable Glycosolated Hemoglobin in Autoimmune Hemolytic Anemia" (PDF). repository.oai.yamaguchi-u.ac.jp. Retrieved 2009-08-31.
- ^ The International Expert Committee (2009). "International expert committee report on the role of the A1C assay in the diagnosis of diabetes". Diabetes Care 32 (7): 1327–1334. doi:10.2337/dc09-9033. PMC 2699715. PMID 19502545.
- ^ Marcus RL, Smith S, Morrell G, Addison O, Dibble LE, Wahoff-Stice D, Lastayo PC (November 2008). "Comparison of combined aerobic and high-force eccentric resistance exercise with aerobic exercise only for people with type 2 diabetes mellitus". Phys Ther 88 (11): 1345–54. doi:10.2522/ptj.20080124. PMC 2579905. PMID 18801851.
External links
- National Diabetes Information Clearinghouse
- American Diabetes Association Standards of Medical Care 2007
- Hemoglobin A1c Test
- A1c (glycated hemoglobin) at Lab Tests Online
- MDRTC Hemoglobin A1C Fact Sheet
- Simple Online A1c Calculator
- Metrika: A1C test for professionals and consumers.
- Developing Point of care HbA1c tests for Diabetes monitoring. Aug 2008 Discusses different test methods
- HbA1c to eAG (estimated Average Glucose) calculator in mmol/l and mg/dl including resources. American Diabetes Association
- What is HbA1c?
- HbA1c: analyte monograph - The Association for Clinical Biochemistry and Laboratory Medicine.
- HbA1c DCCT to IFCC converter
- Hypothyroidism Falsely Raises HbA1c and Glycated Albumin Levels
|
References ranges for blood tests (CPT 82000–84999)
|
|
| Electrolytes |
- Sodium
- Potassium
- Chloride
- Calcium
- Renal function
- Creatinine
- Urea
- BUN-to-creatinine ratio
- Plasma osmolality
- Serum osmolal gap
|
|
| Acid-base |
- Anion gap
- Arterial blood gas
- Base excess
- Bicarbonate
- CO2 content
|
|
| Iron tests |
- Ferritin
- Serum iron
- Transferrin saturation
- Total iron-binding capacity
- Transferrin
- Transferrin receptor
|
|
| Hormones |
- ACTH stimulation test
- Thyroid function tests
- Thyroid-stimulating hormone
|
|
| Metabolism |
|
|
| Cardiovascular |
- Cardiac marker
- CPK-MB test
- Lactate dehydrogenase
- Myoglobin
- Glycogen phosphorylase isoenzyme BB
|
|
| Liver function tests |
- Proteins
- Human serum albumin
- Serum total protein
- ALP
- transaminases
- Bilirubin
|
|
| Pancreas |
|
|
|
Index of the urinary system
|
|
| Description |
- Anatomy
- Physiology
- Development
- Cells
|
|
| Disease |
- Electrolyte and acid-base
- Congenital
- Neoplasms and cancer
- Other
- Symptoms and signs
- Urine tests
- Blood tests
|
|
| Treatment |
- Procedures
- Drugs
- Intravenous fluids
|
|
Index of hormones
|
|
| Description |
- Glands
- Hormones
- thyroid
- mineralocorticoids
- Physiology
- Development
|
|
| Disease |
- Diabetes
- Congenital
- Neoplasms and cancer
- Other
- Symptoms and signs
|
|
| Treatment |
- Procedures
- Drugs
- calcium balance
- corticosteroids
- oral hypoglycemics
- pituitary and hypothalamic
- thyroid
|
|
Index of the heart
|
|
| Description |
- Anatomy
- Physiology
- Development
|
|
| Disease |
- Injury
- Congenital
- Neoplasms and cancer
- Other
- Symptoms and signs
- Blood tests
|
|
| Treatment |
- Procedures
- Drugs
- glycosides
- other stimulants
- antiarrhythmics
- vasodilators
|
|
Index of digestion
|
|
| Description |
- Anatomy
- Physiology
- Development
|
|
| Disease |
- Congenital
- Neoplasms and cancer
- Inflammatory bowel disease
- Gluten sensitivity
- Other
- Symptoms and signs
- Blood tests
|
|
| Treatment |
- Procedures
- Drugs
- anabolic steroids
- antacids
- diarrhoea and infection
- bile and liver
- functional gastrointestinal disorders
- laxatives
- peptic ulcer and reflux
- nausea and vomiting
- other
- Surgery
|
|
|
|
Proteins: hemeproteins
|
|
| Globins |
| Hemoglobin |
| Subunits |
| Alpha locus on 16: |
|
|
| Beta locus on 11: |
|
|
|
| Tetramers |
| stages of development: |
| Embryonic |
- HbE Gower 1 (ζ2ε2)
- HbE Gower 2 (α2ε2)
- HbE Portland I (ζ2γ2)
- HbE Portland II (ζ2β2)
|
|
| Fetal |
- HbF/Fetal (α2γ2)
- HbA (α2β2)
|
|
| Adult |
- HbA (α2β2)
- HbA2 (α2δ2)
- HbF/Fetal (α2γ2)
|
|
|
| pathology: |
- HbH (β4)
- Barts (γ4)
- HbS (α2βS2)
- HbC (α2βC2)
- HbE (α2βE2)
|
|
|
| Compounds |
- Carboxyhemoglobin
- Carbaminohemoglobin
- Oxyhemoglobin/Deoxyhemoglobin
- Sulfhemoglobin
|
|
| Other human |
- Glycated hemoglobin
- Methemoglobin
|
|
| Nonhuman |
- Chlorocruorin
- Erythrocruorin
|
|
|
| Other |
| human: |
- Myoglobin
- Neuroglobin
- Cytoglobin
|
|
| plant: |
|
|
|
|
| Other |
- Cytochrome
- Cytochrome b
- Cytochrome P450
- Hemocyanin
- Methemalbumin
|
|
|
see also disorders of globin and globulin proteins
|
Index of cells from bone marrow
|
|
| Description |
- Immune system
- Cells
- Physiology
- coagulation
- proteins
- granule contents
- colony-stimulating
- heme and porphyrin
|
|
| Disease |
- Red blood cell
- Monocyte and granulocyte
- Neoplasms and cancer
- Histiocytosis
- Symptoms and signs
- Blood tests
|
|
| Treatment |
- Transfusion
- Drugs
- thrombosis
- bleeding
- other
|
|
|
|
Diabetes (E10–E14, 250)
|
|
| Types |
- Type 1
- Type 2
- Gestational diabetes
- Prediabetes
- Impaired fasting glucose
- Impaired glucose tolerance
- Insulin resistance
- LADA
- KPD
- MODY
- Neonatal
|
|
| Blood tests |
- Blood sugar
- Glycosylated hemoglobin
- Glucose tolerance test
- Postprandial glucose test
- Fructosamine
- Glucose test
- C-peptide
- Noninvasive glucose monitor
- Insulin tolerance test
|
|
| Management |
- Diabetic diet
- Anti-diabetic drugs
- Insulin therapy
- intensive
- conventional
- pulsatile
- Cure
- Embryonic stem cells
- Artificial pancreas
- Other
|
|
| Complications |
- Diabetic comas
- Hypoglycemia
- Ketoacidosis
- Hyperosmolar hyperglycemic state
- Diabetic foot
- ulcer
- Neuropathic arthropathy
- Organs in diabetes
- Blood vessels
- Muscle
- Kidney
- Nerves
- Retina
- Heart
- Diabetic skin disease
- Diabetic dermopathy
- Diabetic bulla
- Diabetic cheiroarthropathy
- Neuropathic ulcer
- Hyperglycemia
- Hypoglycemia
|
|
| Other |
|
|
|
Index of hormones
|
|
| Description |
- Glands
- Hormones
- thyroid
- mineralocorticoids
- Physiology
- Development
|
|
| Disease |
- Diabetes
- Congenital
- Neoplasms and cancer
- Other
- Symptoms and signs
|
|
| Treatment |
- Procedures
- Drugs
- calcium balance
- corticosteroids
- oral hypoglycemics
- pituitary and hypothalamic
- thyroid
|
|
|
